Literature DB >> 23960736

Tocilizumab: A new anti-rheumatic drug.

Hisham S Abou-Auda1, Walid Sakr.   

Abstract

Entities:  

Keywords:  Tocilizumab

Year:  2010        PMID： 23960736      PMCID： PMC3730970          DOI： 10.1016/j.jsps.2010.07.009

Source DB:  PubMed          Journal:  Saudi Pharm J        ISSN： 1319-0164            Impact factor:   4.330


× No keyword cloud information.
  12 in total

1.  Tocilizumab may be a potential addition to our weapons against neuro-Behçet's disease.

Authors:  Afshin Borhani Haghighi; Anahid Safari
Journal:  Med Hypotheses       Date:  2008-03-04       Impact factor: 1.538

2.  Tocilizumab for rheumatoid and juvenile idiopathic arthritis.

Authors:  Tim Bongartz
Journal:  Lancet       Date:  2008-03-22       Impact factor: 79.321

3.  Tocilizumab as a potential treatment in Schnitzler syndrome.

Authors:  Nicolas Kluger; Didier Bessis; Bernard Guillot
Journal:  Med Hypotheses       Date:  2009-01-17       Impact factor: 1.538

4.  Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family.

Authors:  Masahiko Mihara; Keiko Kasutani; Makoto Okazaki; Akito Nakamura; Shigeto Kawai; Masamichi Sugimoto; Yoshihiro Matsumoto; Yoshiyuki Ohsugi
Journal:  Int Immunopharmacol       Date:  2005-11       Impact factor: 4.932

5.  Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial.

Authors:  Josef S Smolen; Andre Beaulieu; Andrea Rubbert-Roth; Cesar Ramos-Remus; Josef Rovensky; Emma Alecock; Thasia Woodworth; Rieke Alten
Journal:  Lancet       Date:  2008-03-22       Impact factor: 79.321

6.  Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial.

Authors:  Shumpei Yokota; Tomoyuki Imagawa; Masaaki Mori; Takako Miyamae; Yukoh Aihara; Shuji Takei; Naomi Iwata; Hiroaki Umebayashi; Takuji Murata; Mari Miyoshi; Minako Tomiita; Norihiro Nishimoto; Tadamitsu Kishimoto
Journal:  Lancet       Date:  2008-03-22       Impact factor: 79.321

7.  Evaluation of a biosensor immunoassay for simultaneous characterization of isotype and binding region of human anti-tocilizumab antibodies with control by surrogate standards.

Authors:  Kay Stubenrauch; Uwe Wessels; Rudolf Vogel; Julia Schleypen
Journal:  Anal Biochem       Date:  2009-04-18       Impact factor: 3.365

8.  Early effects of tocilizumab on bone and bone marrow lesions in a collagen-induced arthritis monkey model.

Authors:  Atsuhiko Kato; Saori Matsuo; Hirotake Takai; Yasushi Uchiyama; Masahiko Mihara; Masami Suzuki
Journal:  Exp Mol Pathol       Date:  2008-04-03       Impact factor: 3.362

Review 9.  Interleukin-6: discovery of a pleiotropic cytokine.

Authors:  Tadamitsu Kishimoto
Journal:  Arthritis Res Ther       Date:  2006-07-28       Impact factor: 5.156

Review 10.  Interleukin-6: a new therapeutic target.

Authors:  Josef S Smolen; Ravinder N Maini
Journal:  Arthritis Res Ther       Date:  2006-07-28       Impact factor: 5.156
View more
  2 in total

Review 1.  An Omics Perspective on Molecular Biomarkers for Diagnosis, Prognosis, and Therapeutics of Cholangiocarcinoma.

Authors:  Pattaya Seeree; Phorutai Pearngam; Supeecha Kumkate; Tavan Janvilisri
Journal:  Int J Genomics       Date:  2015-09-02       Impact factor: 2.326

Review 2.  Safety perspectives on presently considered drugs for the treatment of COVID-19.

Authors:  Sophie L Penman; Robyn T Kiy; Rebecca L Jensen; Christopher Beoku-Betts; Ana Alfirevic; David Back; Saye H Khoo; Andrew Owen; Munir Pirmohamed; B Kevin Park; Xiaoli Meng; Christopher E Goldring; Amy E Chadwick
Journal:  Br J Pharmacol       Date:  2020-08-13       Impact factor: 8.739
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.